More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease

被引：1
|
作者：
Kakiuchi, Toshihiko [1 ]
Yoshiura, Masato [1 ]
机构：
[1] Saga Univ, Fac Med, Dept Pediat, 5-1-1 Nabeshima, Saga 8498501, Japan
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 02期
关键词：
ULCERATIVE-COLITIS; REMISSION;
D O I：
10.1016/j.dld.2022.11.004
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：298 / 299
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels
    Huettemann, Eva
    Muzalyova, Anna
    Groehl, Katharina
    Nagl, Sandra
    Fleischmann, Carola
    Ebigbo, Alanna
    Classen, Johanna
    Wanzl, Julia
    Prinz, Friederike
    Mayr, Patrick
    Schnoy, Elisabeth
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [42] Characteristics and First-Line Treatments of Patients With Pyoderma Gangrenosum and Inflammatory Bowel Disease
    Kek, Laura
    Calderon, Gerardo
    Coelho-Prabhu, Nayantara
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S914 - S915
  • [43] Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
    Feagan, Brian G.
    Lasch, Karen
    Lissoos, Trevor
    Cao, Charlie
    Wojtowicz, Abigail M.
    Khalid, Javaria Mona
    Colombel, Jean-Frederic
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (01) : 130 - +
  • [44] More data are needed to use BTX A as first-line treatment
    Carr, Lesley K.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (03): : 209 - 209
  • [45] Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
    Mark Fleisher
    Jan Marsal
    Scott D. Lee
    Laura E. Frado
    Alyssa Parian
    Burton I. Korelitz
    Brian G. Feagan
    Digestive Diseases and Sciences, 2018, 63 : 825 - 833
  • [46] Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
    Fleisher, Mark
    Marsal, Jan
    Lee, Scott D.
    Frado, Laura E.
    Parian, Alyssa
    Korelitz, Burton I.
    Feagan, Brian G.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (04) : 825 - 833
  • [47] Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease
    Steenholdt, Casper
    Lorentsen, Ruben Due
    Petersen, Pernille Norgaard
    Widigson, Ella S. K.
    Kloft, Charlotte
    Klaasen, Rolf Anton
    Brynskov, Jorn
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1088 - 1098
  • [48] VEDOLIZUMAB THERAPY FOR VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE
    Shaul, Eliana
    Conrad, Maire A.
    Dawany, Noor
    Patel, Trusha
    Canavan, Megan C.
    Kelsen, Judith R.
    GASTROENTEROLOGY, 2022, 162 (07) : S1112 - S1112
  • [49] Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment
    Ylisaukko-Oja, T.
    Af Bjorkesten, C. G.
    Erbel, A.
    Nuutinen, H.
    Jussila, A.
    Molander, P.
    Koskela, R.
    Blomster, T.
    Pajala, M.
    Ilus, T.
    Haiko, P.
    Kovac, B.
    Silvola, S.
    Smith, S.
    Jokelainen, J.
    Sipponen, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 758 - 759
  • [50] Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment
    Ylisaukko-Oja, Tero
    af Bjorkesten, Clas-Goran
    Eberl, Anja
    Nuutinen, Heikki
    Jussila, Airi
    Molander, Pauliina
    Koskela, Ritva
    Blomster, Timo
    Pajala, Markku
    Ilus, Tuire
    Haiko, Paula
    Kovac, Bianca
    Silvola, Saija
    Smith, Sarah
    Jokelainen, Jari
    Sipponen, Taina
    HELIYON, 2024, 10 (12)
12345